BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bach HH 4th, Wong YM, Tripathi A, Nevins AM, Gamelli RL, Volkman BF, Byron KL, Majetschak M. Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function. Mol Med 2014;20:435-47. [PMID: 25032954 DOI: 10.2119/molmed.2014.00101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Nassoiy SP, Babu FS, LaPorte HM, Majetschak M. Pharmacological modulation of C-X-C motif chemokine receptor 4 influences development of acute respiratory distress syndrome after lung ischaemia-reperfusion injury. Clin Exp Pharmacol Physiol 2018;45:16-26. [PMID: 28815665 DOI: 10.1111/1440-1681.12845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Brown SM, Meuth AI, Davis JW, Rector RS, Bender SB. Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature. Pharmacol Res 2018;134:100-8. [PMID: 29870805 DOI: 10.1016/j.phrs.2018.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
3 Evans AE, Tripathi A, LaPorte HM, Brueggemann LI, Singh AK, Albee LJ, Byron KL, Tarasova NI, Volkman BF, Cho TY, Gaponenko V, Majetschak M. New Insights into Mechanisms and Functions of Chemokine (C-X-C Motif) Receptor 4 Heteromerization in Vascular Smooth Muscle. Int J Mol Sci 2016;17:E971. [PMID: 27331810 DOI: 10.3390/ijms17060971] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
4 Wong YM, LaPorte HM, Albee LJ, Baker TA, Bach HH 4th, Vana PG, Evans AE, Gamelli RL, Majetschak M. Ubiquitin Urine Levels in Burn Patients. J Burn Care Res 2017;38:e133-43. [PMID: 26204385 DOI: 10.1097/BCR.0000000000000278] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Xu H, Stamova B, Ander BP, Waldau B, Jickling GC, Sharp FR, Ko NU. mRNA Expression Profiles from Whole Blood Associated with Vasospasm in Patients with Subarachnoid Hemorrhage. Neurocrit Care 2020;33:82-9. [PMID: 31595394 DOI: 10.1007/s12028-019-00861-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Walsh SK, Lipina C, Ang SY, Sato M, Chia LY, Kocan M, Hutchinson DS, Summers RJ, Wainwright CL. GPR55 regulates the responsiveness to, but does not dimerise with, α1A-adrenoceptors. Biochem Pharmacol 2021;188:114560. [PMID: 33844984 DOI: 10.1016/j.bcp.2021.114560] [Reference Citation Analysis]
7 Desantis AJ, Weche M, Enten GA, Gao X, Majetschak M. The Chemokine (C-C Motif) Receptor 2 Antagonist INCB3284 Reduces Fluid Requirements and Protects From Hemodynamic Decompensation During Resuscitation From Hemorrhagic Shock. Critical Care Explorations 2022;4:e0701. [DOI: 10.1097/cce.0000000000000701] [Reference Citation Analysis]
8 Sherif MF, Ismail IM, Ata SMS. Expression of CXCR7 in colorectal adenoma and adenocarcinoma: Correlation with clinicopathological parameters. Ann Diagn Pathol 2020;49:151621. [PMID: 32949893 DOI: 10.1016/j.anndiagpath.2020.151621] [Reference Citation Analysis]
9 DeSantis AJ, Enten GA, Gao X, Majetschak M. Chemokine receptor antagonists with α1-adrenergic receptor blocker activity. J Basic Clin Physiol Pharmacol 2021. [PMID: 34144642 DOI: 10.1515/jbcpp-2020-0523] [Reference Citation Analysis]
10 Nassoiy SP, Byron KL, Majetschak M. Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats. J Biomed Sci 2017;24:8. [PMID: 28095830 DOI: 10.1186/s12929-017-0316-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Babu FS, LaPorte HM, Nassoiy SP, Majetschak M. Chemokine (C-X-C motif) receptor 4 regulates lung endothelial barrier permeability during resuscitation from hemorrhagic shock. Physiol Res 2019;68:675-9. [PMID: 31177801 DOI: 10.33549/physiolres.934105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bach HH 4th, Wong YM, LaPorte HM, Gamelli RL, Majetschak M. Pharmacological targeting of chemokine (C-X-C motif) receptor 4 in porcine polytrauma and hemorrhage models. J Trauma Acute Care Surg 2016;80:102-10. [PMID: 26683396 DOI: 10.1097/TA.0000000000000865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Albee LJ, Eby JM, Tripathi A, LaPorte HM, Gao X, Volkman BF, Gaponenko V, Majetschak M. α1-Adrenergic Receptors Function Within Hetero-Oligomeric Complexes With Atypical Chemokine Receptor 3 and Chemokine (C-X-C motif) Receptor 4 in Vascular Smooth Muscle Cells. J Am Heart Assoc 2017;6:e006575. [PMID: 28862946 DOI: 10.1161/JAHA.117.006575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
14 Dalal S, Daniels CR, Li Y, Wright GL, Singh M, Singh K. Exogenous ubiquitin attenuates hypoxia/reoxygenation-induced cardiac myocyte apoptosis via the involvement of CXCR4 and modulation of mitochondrial homeostasis. Biochem Cell Biol 2020;98:492-501. [PMID: 31967865 DOI: 10.1139/bcb-2019-0339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Albee LJ, LaPorte HM, Gao X, Eby JM, Cheng YH, Nevins AM, Volkman BF, Gaponenko V, Majetschak M. Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle. Open Biol 2018;8:170207. [PMID: 29386406 DOI: 10.1098/rsob.170207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
16 Scofield SL, Amin P, Singh M, Singh K. Extracellular Ubiquitin: Role in Myocyte Apoptosis and Myocardial Remodeling. Compr Physiol 2015;6:527-60. [PMID: 26756642 DOI: 10.1002/cphy.c150025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Eby JM, Majetschak M. Effects of ethanol and ethanol metabolites on intrinsic function of mesenteric resistance arteries. PLoS One 2019;14:e0214336. [PMID: 30893362 DOI: 10.1371/journal.pone.0214336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
18 Scofield SLC, Daniels CR, Dalal S, Millard JA, Singh M, Singh K. Extracellular ubiquitin modulates cardiac fibroblast phenotype and function via its interaction with CXCR4. Life Sci 2018;211:8-16. [PMID: 30195032 DOI: 10.1016/j.lfs.2018.09.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Sozzani S, Del Prete A, Bonecchi R, Locati M. Chemokines as effector and target molecules in vascular biology. Cardiovasc Res 2015;107:364-72. [PMID: 25969393 DOI: 10.1093/cvr/cvv150] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
20 Gao X, Enten GA, DeSantis AJ, Majetschak M. Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers. FEBS Lett 2021;595:1863-75. [PMID: 34032285 DOI: 10.1002/1873-3468.14135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Dalal S, Shook PL, Singh M, Singh K. Cardioprotective Potential of Exogenous Ubiquitin. Cardiovasc Drugs Ther 2021;35:1227-32. [PMID: 32910339 DOI: 10.1007/s10557-020-07042-5] [Reference Citation Analysis]
22 Nassoiy SP, Babu FS, LaPorte HM, Byron KL, Majetschak M. Effects of the Kv7 voltage-activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock. Clin Exp Pharmacol Physiol 2018. [PMID: 29702725 DOI: 10.1111/1440-1681.12958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Tripathi A, Vana PG, Chavan TS, Brueggemann LI, Byron KL, Tarasova NI, Volkman BF, Gaponenko V, Majetschak M. Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B-adrenergic receptors controls α1-adrenergic receptor function. Proc Natl Acad Sci U S A 2015;112:E1659-68. [PMID: 25775528 DOI: 10.1073/pnas.1417564112] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
24 Evans AE, Vana PG, LaPorte HM, Kennedy RH, Gamelli RL, Majetschak M. Cardiovascular Responsiveness to Vasopressin and α1-Adrenergic Receptor Agonists After Burn Injury. J Burn Care Res 2017;38:90-8. [PMID: 28045780 DOI: 10.1097/BCR.0000000000000374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Babu FS, Liang X, Enten GA, DeSantis AJ, Volkman BF, Gao X, Majetschak M. Natural and engineered chemokine (C-X-C motif) receptor 4 agonists prevent acute respiratory distress syndrome after lung ischemia-reperfusion injury and hemorrhage. Sci Rep 2020;10:11359. [PMID: 32647374 DOI: 10.1038/s41598-020-68425-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Nevins AM, Subramanian A, Tapia JL, Delgado DP, Tyler RC, Jensen DR, Ouellette AJ, Volkman BF. A Requirement for Metamorphic Interconversion in the Antimicrobial Activity of Chemokine XCL1. Biochemistry 2016;55:3784-93. [PMID: 27305837 DOI: 10.1021/acs.biochem.6b00353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]